Compare UPST & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UPST | GPCR |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2020 | 2023 |
| Metric | UPST | GPCR |
|---|---|---|
| Price | $26.97 | $49.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $45.84 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 3.6M | 697.0K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.25 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,043,857,000.00 | N/A |
| Revenue This Year | $34.45 | N/A |
| Revenue Next Year | $32.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 63.99 | N/A |
| 52 Week Low | $23.97 | $15.80 |
| 52 Week High | $85.31 | $94.90 |
| Indicator | UPST | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 50.72 |
| Support Level | $25.18 | $43.76 |
| Resistance Level | $34.84 | $57.15 |
| Average True Range (ATR) | 1.62 | 2.73 |
| MACD | -0.65 | -0.61 |
| Stochastic Oscillator | 1.37 | 36.26 |
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.